# Hepatology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Frazier (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX004-SYN-TD
- Date: 2008-02-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Anjali Deshpande, MD, Hepatology
- Urgency: Within two weeks, with elastography and an ultrasound the same day

## Referral question

High FIB-4 (3.43) with a mildly raised AST and low platelets at the yearly liver check in a 64-year-old man with type 2 diabetes, hypertension, low HDL, high triglycerides and obesity, who drinks little. Please stage his liver disease with elastography and advise on surveillance and treatment. **S**

## Questions for the consultant

1. How advanced is the fibrosis, and is this MASLD?
2. Does he need liver cancer surveillance, and how often?
3. Does he need screening for varices or a beta-blocker?
4. Which diabetes medicine would you favor for his liver, and are metformin and atorvastatin safe?
5. Which vaccines and other precautions do you advise?

## Pertinent history

Former professional heavyweight boxer who runs a gym. Type 2 diabetes for about twelve years on metformin (A1c 8.4%); hypertension on lisinopril, above goal; LDL 132 mg/dL, HDL 38, triglycerides 210; BMI 31.4. Alcohol: one or two beers on some weekends (AUDIT-C 2); never smoked; no drug use. No history of jaundice, swelling or bleeding. Today: AST 48 and ALT 42 U/L, alkaline phosphatase 96, albumin 4.0 g/dL, bilirubin 0.9 mg/dL, platelets 138, hemoglobin 14.2, creatinine 1.08 mg/dL (eGFR 77), urine albumin-to-creatinine ratio 18 mg/g. FIB-4 3.43. Atorvastatin 40 mg started today. Hepatitis B, hepatitis C and HIV tests, iron studies and autoimmune tests sent. Reduced vision in the left eye since a cataract found at 20. **S**

- Joe Frazier was born on January 12, 1944, in Beaufort County, South Carolina, the eleventh child of a sharecropping family. **D**
- As a teenager he moved to Philadelphia, where he had relatives, and worked in a slaughterhouse, where he punched sides of beef in the cold room. **D**
- He won the heavyweight gold medal at the 1964 Olympic Games in Tokyo, fighting the final with a broken left thumb. **D**
- Later in 1964 he learned that he had a cataract in his left eye; visually impaired, he turned professional anyway. The cataract grew worse, and by 1975, according to his eye doctor, his vision was 20/50 in the right eye and 20/400 in the left. **D**
- He became undisputed world heavyweight champion in February 1970 and held the title until January 1973, defending it four times; he retired in 1976 after a professional record of 32 wins, 4 losses and 1 draw, with 27 knockouts, and returned for a single bout in 1981. **D**
- His three-fight rivalry in the 1970s included a 1971 victory that handed his opponent his first professional defeat; in the third fight, in Manila in 1975, he could no longer see, and his trainer would not let him come out for the fifteenth round. **D**
- In later life he lived in Philadelphia, where he owned and ran a boxing gym, and he had financial trouble. **D**
- During his life it was reported publicly that he had diabetes and high blood pressure. **D**
- He published an autobiography, Smokin' Joe, in 1996. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Hemoglobin A1c: 8.4% (high); Glucose (fasting): 168 mg/dL (high); Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 1.08 mg/dL; eGFR (CKD-EPI 2003, no race term): 77 mL/min/1.73 m²; Urine albumin-to-creatinine ratio: 18 mg/g; Total cholesterol: 212 mg/dL (high); LDL cholesterol: 132 mg/dL (high); HDL cholesterol: 38 mg/dL (low); Triglycerides: 210 mg/dL (high); AST: 48 U/L (high); ALT: 42 U/L; Alkaline phosphatase: 96 U/L; Albumin: 4 g/dL; Total bilirubin: 0.9 mg/dL; Hemoglobin: 14.2 g/dL; Platelets: 138 10*3/uL (low); Vitamin B12: 340 pg/mL; PHQ-9: 4; AUDIT-C: 2. All results are synthetic.

BP 152/92 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 104 kg; BMI 31.4 kg/m². All vital signs are synthetic.

## Current medications

- Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years **S**
- Lisinopril 20 mg oral tablet, one tablet daily; taken for years **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**

## Plan so far

- Diabetes: continue metformin, an A1c every three months until at goal and then every six months, diabetes self-management education, a vitamin B12 check on long-term metformin, and no medicine that causes low blood sugar. Guideline: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Liver assessment: FIB-4 from the yearly liver tests, then transient elastography if FIB-4 is 1.3 or higher; hepatitis B, hepatitis C and HIV tests, iron studies, and an alcohol history. Guideline: 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Blood pressure: a validated home monitor with a large cuff, readings twice a day for a week, a goal below 130/80 mmHg, and less salt. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Cardiovascular risk: atorvastatin 40 mg with a lipid panel at four to twelve weeks; a baseline ECG; aspirin for primary prevention not used because of bleeding risk. Guideline: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Kidneys: eGFR by the race-free CKD-EPI 2003 equation and urine albumin-to-creatinine ratio at least yearly, and potassium and creatinine on lisinopril. Guideline: 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Eyes and feet: a dilated eye examination at the eye clinic, a comprehensive foot examination yearly, daily foot checks and callus care. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026) **S**
- Brain health: a documented cognitive screen at the preventive visit, blood pressure and glucose control, sleep, hearing and mood checks, and an honest conversation that chronic traumatic encephalopathy cannot be diagnosed during life. Guideline: National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Cost and access: low-cost generics, 90-day supplies, and help with coverage for any brand-name medicine. Guideline: 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026) **S**
